Skip to content
DataLookout
Menu

NCT06480383

Study of ITI-1284 as an Adjunctive Treatment in Patients With Generalized Anxiety Disorder

StatusRecruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 9 versions: 8 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 56 → 59 locations
  2. Notable Eligibility criteria expanded, about 18 words
    • Study completion pushed from Mar 23, 2027 to Oct 21, 2027
    • Secondary endpoints: details revised at 1 of 1 entry
    • Site details revised at 1 of 56 sites
  3. Notable Eligibility criteria expanded, about 48 wordsv6 Show 4 more changesShow less
    • Trial sites reduced: 69 → 56 locations
    • Primary completion moved earlier from Jun 2027 to Mar 16, 2027
    • Study completion moved earlier from Jun 2027 to Mar 23, 2027
    • Study description shortened, about 75 words
  4. Minor Study sites: 30 to 69v5
  5. Minor Study sites: 28 to 30v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 29 to 28
    • Primary and study completion dates pushed to Jun 2027
    v3
  2. Minor Study sites: 27 to 29
    • Start date changed from estimate of Jun 2024 to Aug 5, 2024
    • Interventions: ITI-1284 10 mg (Drug), ITI-1284 20 mg (Drug), Placbo (Drug) to ITI-1284 10 mg (Drug), ITI-1284 20 mg (Drug), Placebo (Drug)
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Hamilton Anxiety Rating Scale (HAM-A)
Timeframe: Week 6

Secondary (1)

Clinical Global Impression Scale-Severity (CGI-S)

Arms and interventions

ITI-1284 10 mgExperimental
ITI-1284 20 mgExperimental
PlaceboPlacebo comparator

Drugs: ITI-1284 10 mg, ITI-1284 20 mg, Placebo

Sites

59 sites in 6 countries

United States 25, Bulgaria 13, Serbia 7, Poland 6, Czechia 5, Finland 3